“AC Immune and Lilly’s partnership will combine AC Immune’s proprietary Morphomer platform technology with Lilly’s commercial and clinical development capabilities. The collaboration with focus on AC’s lead molecule ACI-3024, which demonstrated tau aggregation inhibition in preclinical models.”
Read the full story at outsourcing-pharma.com
AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ
- Braincheck Raises Another $1.5 Million to Bring Artificial Intelligence to Dementia Care | PR Web